Breaking News, Collaborations & Alliances

Ablynx, Spirogen In ADC Research Pact

Will combine technologies to evaluate anti-cancer drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ablynx and Spirogen Ltd. have entered a research collaboration to evaluate a novel anti-cancer drug conjugate combining Spirogen’s cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies generated using Ablynx’s technology platform.   Ablynx will provide access to novel Nanobodies against a specific, undisclosed cancer target and Spirogen will provide access to its proprietary cytotoxic warheads (PBDs) and conjugation technologies. Both compan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters